Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel for advanced NSCLC after failure of first-line immunotherapy + platinum chemotherapy
ChiCTR2300077992Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Progression-free survival time (PFS) and Objective response rate (ORR). Started Jan 2020; status: completed.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300077992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077992.